FDA Flags Legacy Pharmaceuticals for GMP Violations

Drug Industry Daily
A A
The FDA observed various GMP deficiencies in an inspection of a Legacy Pharmaceuticals Switzerland facility, including problems with sterility, maintenance and discrepancy investigations.

To View This Article:

Login

Subscribe To Drug Industry Daily